Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tourmaline Bio is a clinical-stage biotechnology company developing inhaled therapies for inflammatory diseases, with lead asset TOUR006 targeting severe asthma and chronic obstructive pulmonary disease (COPD). The company is advancing a differentiated IL-6 inhibitor delivered via inhalation to minimize systemic exposure while maximizing local efficacy in respiratory tissues. With no revenue and negative cash flow of $100M annually, the stock trades on clinical trial readouts, regulatory milestones, and partnership potential.
Tourmaline operates a classic biotech development model: raise capital through equity offerings, invest in clinical trials to demonstrate safety/efficacy, then either commercialize independently or partner with larger pharmaceutical companies for royalties and milestone payments. The inhaled delivery mechanism targets a differentiated positioning versus systemic IL-6 inhibitors, potentially commanding premium pricing ($30K-50K annually per patient estimate) if approved. Current cash runway extends through multiple Phase 2 readouts based on $24.68 current ratio and minimal debt. Monetization depends entirely on successful clinical outcomes and FDA approval, with peak sales potential in the $500M-1B range if TOUR006 captures 5-10% of the severe asthma biologics market.
TOUR006 Phase 2 clinical trial data readouts for severe asthma and COPD - primary endpoints on lung function (FEV1) and exacerbation rates
FDA regulatory interactions including IND clearances, Fast Track/Breakthrough Therapy designations, or Phase 3 trial design guidance
Strategic partnership announcements with major pharmaceutical companies for co-development or commercialization rights
Capital raises and cash runway updates - equity offerings dilute but extend operational timeline
Competitive data from rival IL-6 inhibitors or inhaled biologics that validate or challenge the therapeutic approach
Broader biotech sector sentiment and risk appetite for clinical-stage assets
Clinical trial failure risk - TOUR006 must demonstrate statistically significant efficacy and acceptable safety in Phase 2/3 trials; failure rates exceed 90% for clinical-stage assets industry-wide
Regulatory approval uncertainty - FDA may require additional studies, impose restrictive labeling, or reject applications based on benefit-risk assessment
Reimbursement pressure - payers increasingly scrutinize high-cost biologics; formulary access and pricing negotiations could limit commercial potential even if approved
Inhaled biologic delivery complexity - manufacturing scale-up, device reliability, and patient adherence challenges specific to inhalation route
Established severe asthma biologics (Dupixent, Nucala, Fasenra) have multi-year head starts with proven efficacy and physician familiarity; TOUR006 must demonstrate clear differentiation
Other IL-6 pathway inhibitors in development from larger pharmaceutical companies with superior resources and commercialization infrastructure
Oral small molecule competitors targeting similar inflammatory pathways may offer convenience advantages over inhaled biologics
Cash runway risk - $100M annual burn rate requires periodic equity raises that dilute existing shareholders; market windows may close during biotech downturns
Single-asset concentration - TOUR006 represents substantially all enterprise value; pipeline diversification remains limited
Negative ROE of -30.5% and ROA of -32.9% reflect ongoing losses that will persist until potential commercialization in 2028-2030 timeframe
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital as risk appetite contracts, (2) patient enrollment if economic stress affects healthcare access, and (3) ultimate commercial uptake if approved during weak healthcare spending environments. The 87% one-year return and 210% six-month return reflect biotech sector rotation rather than economic cycle exposure.
High sensitivity through valuation multiples rather than operations. Pre-revenue biotechs are valued on discounted future cash flows 5-10 years out, making them highly sensitive to discount rates. Rising rates from current levels compress NPV of potential approvals, while falling rates expand multiples. The -$100M annual cash burn is unaffected by rates (zero debt per 0.00 D/E ratio), but equity financing costs and investor appetite fluctuate significantly with the risk-free rate. Current 30816x P/S ratio reflects pure option value on clinical success rather than fundamental earnings.
Minimal - Zero debt and $24.68 current ratio indicate no near-term credit dependency. Future capital needs will be met through equity markets rather than debt financing given pre-revenue status. Credit conditions affect the company indirectly through biotech sector liquidity and SPAC/IPO market functionality.
growth/momentum - The 210% six-month return and 104% three-month return attract speculative biotech investors focused on binary clinical catalysts rather than fundamental cash flow analysis. Typical shareholders include specialized healthcare hedge funds, biotech-focused mutual funds, and retail momentum traders. The $1.2B market cap with zero revenue represents pure option value on regulatory approval. Not suitable for value or income investors given negative margins and no dividend potential.
high - Clinical-stage biotechs routinely experience 30-50% single-day moves on trial data releases. The stock exhibits extreme event-driven volatility around FDA interactions, conference presentations, and competitive developments. Beta likely exceeds 2.0 relative to broader biotech indices. Recent 87% one-year return demonstrates momentum characteristics, but drawdown risk remains substantial if trials disappoint.
